1 day Ago By ABMN Staff
Virtu Financial LLC purchased a new stake in Theratechnologies Inc. ( NASDAQ:THTX – Free Report ) in the fourth quarter, Holdings Channel.com reports.
The firm purchased 21,902 shares of the company’s stock, valued at approximately $40,000. Other hedge funds have also recently bought and sold shares of the company. Harbour Investments Inc.
increased its position in shares of Theratechnologies by 20.0% in the 4th quarter. Harbour Investments Inc.
now owns 87,772 shares of the company’s stock worth $159,000 after purchasing an additional 14,655 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Theratechnologies in the fourth quarter valued at about $27,000.
Wealthspire Advisors LLC raised its stake in Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after buying an additional 20,000 shares in the last quarter.
Finally, National Bank of Canada FI raised its stake in Theratechnologies by 29.4% during the third quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after buying an additional 42,435 shares in the last quarter.
Theratechnologies Stock Performance Shares of NASDAQ:THTX opened at $1.40 on Wednesday. The company’s fifty day moving average is $1.
63 and its two-hundred day moving average is $1.50. Theratechnologies Inc.
has a 1-year low of $1.08 and a 1-year high of $2.18.
The stock has a market capitalization of $64.37 million, a price-to-earnings ratio of -14.00 and a beta of 1.
24. Wall Street Analysts Forecast Growth Read Our Latest Report on THTX Theratechnologies Company Profile ( Free Report ) Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Featured Stories Want to see what other hedge funds are holding THTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theratechnologies Inc. ( NASDAQ:THTX – Free Report ).
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter ..
_8.jpg?itok=wp-xhXRB)
